<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03225300</url>
  </required_header>
  <id_info>
    <org_study_id>CE17194B</org_study_id>
    <nct_id>NCT03225300</nct_id>
  </id_info>
  <brief_title>Simultaneous Integrated Boost in Malignant Glioma Patients Treated With Chemoradiation</brief_title>
  <official_title>Evaluation the Prognostic Significance of High Radiation Dose in Malignant Glioma Patients Treated With Chemoradiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taichung Veterans General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Simultaneous integrated boost (SIB), a field-in-field escalation technique, has been
      introduced to deliver higher radiation dose to the certain part of target with the same
      fractionation scheme. The aim of this study was to investigate the value of chemoradiation
      (CCRT) using SIB in glioblastoma and the correlation with surgical extent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The SIB technique provides the higher radiobiological effect with the same fractionation
      scheme, i.e. 69 Gy over 6 weeks, which might increase the loco-regional control. Besides, the
      co-registration with magnetic resonance imaging (MRI) strengthens the precision of target
      delineation as well as higher possibility to spare adjacent normal brain tissue.

      In this protocol, the newly diagnosed, primary glioblastoma patients received SIB 69 Gy/30
      fractions to preoperative tumor bed and surgical cavity, while 60 Gy/30 fractions were
      covering preoperatively edematous area. To determine the status of surgical extent,
      postoperative CT scan and MRI was acquired within 72 hours and at 4th week after surgery.
      During the period of chemoradiation, acute neurotoxicity and hematological toxicity was
      assessed as well.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2005</start_date>
  <completion_date type="Anticipated">December 31, 2017</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A prospectively single arm in single institution.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free survival rate</measure>
    <time_frame>at the end of first year</time_frame>
    <description>Actual one-year progression-free survival rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical extent</measure>
    <time_frame>CT within 72 hours and MRI at 4th week after surgery</time_frame>
    <description>No contrast-enhanced area: gross total resection; Any contrast-enhanced area: residual tumor</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Chemoradiation</condition>
  <arm_group>
    <arm_group_label>Simultaneous integrated boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this protocol, the newly diagnosed, primary glioblastoma patients receive SIB 69 Gy/30 fractions to preoperative tumor bed and surgical cavity, while 60 Gy/30 fractions were covering preoperatively edematous area. PTV is 5 mm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Simultaneous integrated boost</intervention_name>
    <description>Simultaneous integrated boost (SIB), a field-in-field escalation technique, has been introduced to deliver higher radiation dose to the certain part of target with the same fractionation scheme.</description>
    <arm_group_label>Simultaneous integrated boost</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 years or above

          -  newly diagnosed, tissue-proven glioblastoma

          -  pre-radiotherapy Karnofsky performance score (KPS) ≧60.

        Exclusion Criteria:

          -  any previous history of chemotherapy or radiotherapy

          -  receiver of any investigating agents

          -  recurrent GBM

          -  any second malignancies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weir Chiang You, M.D. Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Dempartment of Radiation Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weir Chiang You, M.D. PhD</last_name>
      <phone>886-4-23592525</phone>
      <phone_ext>5602</phone_ext>
      <email>bigjohnyou@vghtc.gov.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Bauchet L, Mathieu-Daudé H, Fabbro-Peray P, Rigau V, Fabbro M, Chinot O, Pallusseau L, Carnin C, Lainé K, Schlama A, Thiebaut A, Patru MC, Bauchet F, Lionnet M, Wager M, Faillot T, Taillandier L, Figarella-Branger D, Capelle L, Loiseau H, Frappaz D, Campello C, Kerr C, Duffau H, Reme-Saumon M, Trétarre B, Daures JP, Henin D, Labrousse F, Menei P, Honnorat J; Société Française de Neurochirurgie (SFNC); Club de Neuro-Oncologie of the Société Française de Neurochirurgie (CNO-SFNC); Société Française de Neuropathologie (SFNP); Association des Neuro-Oncologues d'Expression Française (ANOCEF). Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol. 2010 Jul;12(7):725-35. doi: 10.1093/neuonc/noq030. Epub 2010 Apr 2.</citation>
    <PMID>20364023</PMID>
  </reference>
  <reference>
    <citation>Monjazeb AM, Ayala D, Jensen C, Case LD, Bourland JD, Ellis TL, McMullen KP, Chan MD, Tatter SB, Lesser GJ, Shaw EG. A phase I dose escalation study of hypofractionated IMRT field-in-field boost for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):743-8. doi: 10.1016/j.ijrobp.2010.10.018. Epub 2011 Jan 13.</citation>
    <PMID>21236604</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>July 20, 2017</last_update_submitted>
  <last_update_submitted_qc>July 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>Chemoradiation</keyword>
  <keyword>Simultaneous integrated boost</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

